Introduction
============

As a high-grade type and mesenchymally-derived bone sarcoma ([@b1-ijmm-42-01-0021]), osteosarcoma (OS) is the most prevalent primary bone cancer and the 8th most frequent type of cancer affecting young patients ([@b2-ijmm-42-01-0021]). Being characterized by a high malignant degree, rapid progression and a poor survival, OS consists up to 15% of all solid extracranial cancers in patients aged 15--19 years ([@b3-ijmm-42-01-0021],[@b4-ijmm-42-01-0021]). Thus, it is necessary to identify biomarkers involved in OS.

DNA repair gene RecQ protein-like 4 (*RECQL4*) is overexpressed in OS, and its overexpression is related to overall genomic instability ([@b5-ijmm-42-01-0021]). Human epidermal growth factor receptor 2 (*Her-2/neu*) expression can induce lung metastasis in OS and may be related to gene amplification ([@b6-ijmm-42-01-0021]). Overexpressed c-fos (*FOS*) and runt-related transcription factor 2 (*RUNX2*) may play a role in OS; in particular, *RUNX2* expression may serve as a marker of chemotherapy failure in patients with OS ([@b7-ijmm-42-01-0021],[@b8-ijmm-42-01-0021]). The cell cycle regulator, CDC5 cell division cycle 5-like (*CDC5L*), is essential for the G2-M transition and may be potential oncogene for the 6p12-p21 amplicon in OS ([@b9-ijmm-42-01-0021]). It has been reported that genes with the function of transcription factors (TFs) can also play a role in OS, such as Yin Yang 1 (*YY1*), which is expressed in the early process of osteoblastic transformation and its detection may be used as a promising diagnostic method in human OS ([@b10-ijmm-42-01-0021]). In addition, the TF osterix (*Osx*) can suppress the lung migration of OS tumor cells; thus, the expression of *Osx* may be implicated in the growth and metastasis of OS ([@b11-ijmm-42-01-0021]).

There are also many studies which have investigated the direct or indirect effect of microRNAs (miRNAs or miRs) on OS. For example, by targeting matrix metalloprotease 13 (*MMP13*) and B-cell CLL/lymphoma 2 (*Bcl-2*), *miR-143* may be involved in the lung metastasis of human OS cells and may thus be used as a target in cancer therapy ([@b12-ijmm-42-01-0021],[@b13-ijmm-42-01-0021]). In addition, downregulated *miR-199a-3p* may function in the growth and proliferation of OS cells; hence, restoring the function of *miR-199a-3p* may contribute to the treatment of OS ([@b14-ijmm-42-01-0021]). By mediating reversion-inducing-cysteine-rich protein with kazal motifs (*RECK*), *miR-21* plays an important role in regulating cell invasion and migration in OS and may be a potential therapeutic target ([@b15-ijmm-42-01-0021]). By regulating *c-Met* and other genes, *miR-34a* can function as a tumor suppressor gene and suppresses the pulmonary metastasis of OS; thus, it may be a useful gene therapeutic agent ([@b16-ijmm-42-01-0021]).

In 2012, Namløs *et al* ([@b17-ijmm-42-01-0021]) used global microarray analyses to identify the differentially expressed miRNAs (DE-miRNAs) between OS cell lines and normal bones, and obtained 177 DE-miRNAs. In this study, using the same data by Namløs *et al* ([@b17-ijmm-42-01-0021]), we aimed to further screen the differentially expressed genes (DEGs) and DE-miRNAs. The potential functions of the DEGs were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Subsequently, the interaction associations of the proteins encoded by the DEGs were investigated by protein-protein interaction network (PPI) network and modules of PPI network. In addition, the TF-DEG regulatory network, DE-miRNA-DEG regulatory network and miRNA-function collaborative network were separately constructed to obtain key DEGs and DE-miRNAs.

Data collection methods and analysis
====================================

Microarray data
---------------

The microarray of GSE28425 deposited by Namløs *et al* ([@b17-ijmm-42-01-0021]) was downloaded from Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>), which included the miRNA expression profile, GSE28423, and the mRNA expression profile, GSE28424. Each of the expression profiles included a collection of 19 OS cell lines and 4 normal bones. GSE28423 was based on the platform of GPL8227 Agilent-019118 Human miRNA Microarray 2.0 G4470B (Agilent Technologies Inc., Santa Clara, CA, USA). GSE28424 was based on the platform of GPL13376 Illumina HumanWG-6 v2.0 expression beadchip (Illumina, San Diego, CA, USA). The OS samples were from a panel collected within EuroBoNeT and from the Norwegian Radium Hospital. Meanwhile, normal bones were from Capital Biosciences or from amputations of cancer patients at the University College London and Norwegian Radium Hospital.

Screening of DEGs and DE-miRNAs
-------------------------------

After GSE28425 was downloaded, the microarray data was pre-processed using the limma package ([@b18-ijmm-42-01-0021]) in Bioconductor (<http://www.bioconductor.org/packages/release/bioc/html/limma.html>). In brief, the pre-processing process included Background Correction, Quantile Normalization and Probe Summarization. The limma (linear models for microarray data) package ([@b18-ijmm-42-01-0021]) was used to analyze the DEGs and DE-miRNAs between the OS cell lines and normal bones. The FDR (that is, adjusted p-value) \<0.05 and \|log2fold-change (FC)\| \>1 were used as the cut-off criteria. Screening the tumor suppressor (TS) gene (<http://bioinfo.mc.vanderbilt.edu/TSGene/download.cgi>) ([@b19-ijmm-42-01-0021]) and tumor-associated gene (TAG) (<http://www.binfo.ncku.edu.tw/TAG/GeneDoc.php>) ([@b20-ijmm-42-01-0021]) databases, the DEGs associated with tumors were screened and annotated.

Functional and pathway enrichment analysis
------------------------------------------

GO provides controlled and structured vocabularies which model biological process (BP), cell components (CC) and molecular function (MF) ([@b21-ijmm-42-01-0021]). KEGG is a database containing 16 main databases, roughly divided into systems information, chemical information and genomic information ([@b22-ijmm-42-01-0021]). GO functional enrichment analyses, which involved the BP, MF and CC categories, as well as KEGG pathway enrichment analyses were performed for the DEGs and the DE-miRNAs. A p-value \<0.05 was used as the cut-off criterion.

PPI network and module construction
-----------------------------------

The interaction associations of the proteins encoded by the DEGs were searched using STRING online software (<http://string-db.org>; v9.05) ([@b23-ijmm-42-01-0021]), and the combined score of \>0.7 was used as the cut-off criterion. The PPI network was visualized using Cytoscape software (<http://www.cytoscape.org>) ([@b24-ijmm-42-01-0021]). Modules of the PPI network were screened using the ClusterOne plugin ([@b25-ijmm-42-01-0021]) in Cytoscape, and the significant p-value of the modules were set to 1.1E-6.

TF-DEG regulatory network construction
--------------------------------------

Human TF-gene regulatory pairs were downloaded from the UCSC database (<http://genome.ucsc.edu/>) ([@b26-ijmm-42-01-0021]). The DEGs which can also function as TFs and their target genes were then identified. Moreover, Cytoscape software ([@b24-ijmm-42-01-0021]) was used to visualize the the TF-DEG regulatory network.

DE-miRNA-DEG regulatory network construction
--------------------------------------------

By comparing the experimental validated miRNA-mRNA pairs in the miRecords (<http://www.mirecords.umn.edu>) ([@b27-ijmm-42-01-0021]) and mirWalk (<http://mirwalk.uni-hd.de/>) ([@b28-ijmm-42-01-0021]) databases, pairs of DE-miRNAs from the miRNA expression profile, GSE28423, and DEGs from the mRNA expression profile, GSE28424, were obtained. The DE-miRNA-DEG pairs should appear in either miRecords database or mirWalk database.

miRNA-function collaborative network construction
-------------------------------------------------

According to the functional enrichment results of the DE-miRNAs, the DE-miRNAs which targeted the genes involved in one BP term were identified. Subsequently, miRNA-function collaborative network was constructed. A p-value \<0.01 was used as the cut-off criterion.

Results
=======

DEGs analysis
-------------

Compared with normal bones, there were 1,609 DEGs (including 774 upregulated and 835 downregulated mRNAs) and 149 DE-miRNAs (including 76 upregulated and 73 downregulated miRNAs) screened in the OS cell lines. The DEGs associated with tumors were annotated and are listed in [Table I](#tI-ijmm-42-01-0021){ref-type="table"}. Importantly, upregulated FOS-like antigen 1 (*FOSL1*) also had the function of an oncogene.

Functional and pathway enrichment analysis
------------------------------------------

The top 5 enriched GO functions in the BP, CC and MF categories separately for the upregulated and downregulated genes are listed in [Table II](#tII-ijmm-42-01-0021){ref-type="table"}. For the upregulated genes, the enriched functions included cell cycle (p=0), intracellular membrane-bounded organelle (p=0) and catalytic activity (p=3.05E-10). For the downregulated genes, the enriched functions included cell activation (p=0), extracellular region (p=0) and carbohydrate derivative binding (p=1.55E-08).

The top 10 enriched KEGG pathways separately for the upregulated and downregulated genes are also listed in [Table II](#tII-ijmm-42-01-0021){ref-type="table"}. For the upregulated genes, the enriched pathways included metabolic pathways (p=1.14E-06), steroid biosyn-thesis (p=2.02E-05) and spliceosome (p=0.003765459). For the downregulated genes, the enriched pathways included cytokine-cytokine receptor interaction (p=3.76E-06) and osteoclast differentiation (p=7.87E-06).

PPI network and module analysis
-------------------------------

The PPI network of the DEGs had 844 nodes and 3,400 interactions. In particular, MAD2 mitotic arrest deficient-like 1 (MAD2L1, degree, 65), cyclin B1 (CCNB1, degree, 65) and aurora kinase A (AURKA, degree, 64) had high degrees in the PPI network. In addition, 3 modules (module 1, module 2 and module 3) of the PPI network were screened ([Fig. 1](#f1-ijmm-42-01-0021){ref-type="fig"}). In module 1, TAO kinase 1 (TAOK1) was the only downregulated gene. The enriched KEGG pathways for the DEGs in module 1 included oocyte meiosis (p=2.04E-08), cell cycle (p=4.16E-08) and progesterone-mediated oocyte maturation (p=0.000112373) ([Table III](#tIII-ijmm-42-01-0021){ref-type="table"}). In module 2, guanine nucleotide binding protein, α inhibiting 1 (GNAI1) and regulator of G-protein signaling 20 (RGS20) were downregulated. The enriched KEGG pathways for the DEGs in module 2 included chemokine signaling pathway (p=0) and cytokine-cytokine receptor interaction (p=9.77E-15) ([Table III](#tIII-ijmm-42-01-0021){ref-type="table"}). Furthermore, the DEGs involved in module 3 were all upregulated genes. The enriched KEGG pathways for the DEGs in module 3 included ribosome (p=1.26E-12) and protein processing in endoplasmic reticulum (p=0.043084724) ([Table III](#tIII-ijmm-42-01-0021){ref-type="table"}).

TF-DEG regulatory network analysis
----------------------------------

The TF-DEG regulatory network had 311 interactions (involving 10 transcription factors and 285 DEGs) ([Fig. 2](#f2-ijmm-42-01-0021){ref-type="fig"}). Importantly, the TFs, signal transducer and activator of transcription 3 (*STAT3*, degree, 158) and forkhead box A1 (*FOXA1*, degree, 106) targeted the most DEGs.

DE-miRNA-DEG regulatory network analysis
----------------------------------------

The DE-miRNA-DEG regulatory network involved 23 upregulated miRNAs and 64 downregulated miRNAs ([Fig. 3](#f3-ijmm-42-01-0021){ref-type="fig"}). In the DE-miRNA-DEG regulatory network, downregulated *miR-1* targeted and activated many DEGs. Moreover, downregulated estrogen receptor 1 (*ESR1*) was targeted by several high-expressed miRNAs, including miR-221, miR-20b and miR-18a. The enriched GO functions for the upregulated and downregulated miRNAs are listed in [Table IV](#tIV-ijmm-42-01-0021){ref-type="table"}. For the upregulated miRNAs, the enriched functions included positive regulation of retinoic acid receptor signaling pathway (p=0.000211583) and type 1 metabotropic glutamate receptor binding (p=0.000150457). For the downregulated miRNAs, the enriched functions included response to inactivity (p=0.001989302) and potassium ion binding (p=0.006643278).

miRNA-function collaborative network analysis
---------------------------------------------

The miRNA-function collaborative networks of upregulated ([Fig. 4](#f4-ijmm-42-01-0021){ref-type="fig"}) and downregulated ([Fig. 5](#f5-ijmm-42-01-0021){ref-type="fig"}) miRNAs were constructed, respectively. In the miRNA-function collaborative networks of upregulated miRNAs, myeloid dendritic associated functions were targeted by miR-128 and miR-125a-5p.

Discussion
==========

In this study, we screened 1,609 DEGs (including 774 upregulated and 835 downregulated mRNAs) and 149 DE-miRNAs (including 76 upregulated and 73 downregulated miRNAs) in the OS cell lines compared with normal bones. Importantly, upregulated *FOSL1* also had the function of an oncogene. MAD2L1 (degree, 65) and AURKA (degree, 64) had higher degrees in the PPI network of the DEGs. In the DE-miRNA-DEG regulatory network, downregulated *miR-1* targeted many DEGs and *ESR1* were targeted by several highly expressed miRNAs. Moreover, in the miRNA-function collaborative networks of upregulated miRNAs, *miR-128* targeted myeloid dendritic associated functions.

In the PPI network of the DEGs, MAD2L1 and AURKA were with high degrees. The overexpression of Mad2 can induce early dyscrasia, lung metastasis and poor survival in OS ([@b29-ijmm-42-01-0021]). The knockdown of *Mad2* leads to OS cell death through apoptosis associated with *Rad21* cleavage; thus, *Mad2* may serve as a target for cancer therapy ([@b30-ijmm-42-01-0021]). *AURKA* can promote cell cycle and suppress cell apoptosis, and the inhibition of *AURKA* by specific short hairpin RNA (shRNA) may be a promising therapeutic strategy of OS ([@b31-ijmm-42-01-0021]). Furthermore, in the TF-DEG regulatory network, the TF, *STAT3*, targeted the most DEGs. By binding to the promoter region of *miR-125b* and acting as a transactivator, *STAT3* regulates *miR-125b* which serves as a potential target in the therapy of OS ([@b32-ijmm-42-01-0021]). The overexpression of phosphorylated-STAT3 in OS cells is implicated in poor prognosis and may function as a prognostic indicator and therapeutic target for OS ([@b33-ijmm-42-01-0021],[@b34-ijmm-42-01-0021]). These data suggest that *MAD2L1*, *AURKA* and *STAT3* may be closely associated with OS.

Some other molecules have also been involved in OS. The deregulation of *miR-1* and *miR-133b* may correlate with cell cycle and cell proliferation of OS by mediating c-met (MET) protein expression ([@b35-ijmm-42-01-0021]). Through directly regulating PTEN/AKT signaling, miR-128 functions in the proliferation of human OS cells ([@b36-ijmm-42-01-0021]). The hypermethylation of p14ARF and ESR1 separately correlates with the absence of metastases at diagnoses and poor survival, therefore, p14ARF and ESR1 hypermethylation may be used as prognostic indicators for in OS ([@b37-ijmm-42-01-0021]). In 143B OS cells, phosphorylated and activated *c-Jun* and *Fra-1* (also known as *FOSL1*) can induce *MMP1* gene expression which may be a target for invasive and pulmonary metastases of OS, therefore, phosphorylated *c-Jun* and *Fra-1* may affect invasion of OS through mediating *MMP1* ([@b38-ijmm-42-01-0021]).

In conclusion, this study identified key genes or miRNAs involved in OS. We screened 1,609 DEGs and 149 DE-miRNAs in the OS cell lines compared with normal bones. Besides, some molecules may correlate with OS, such as *MAD2L1*, *AURKA*, *STAT3*, *ESR1*, *FOSL1*, *miR-1* and *miR-128*. However, experimental researches are still necessary to validate the functions of these molecules in OS.

Competing interests
===================

The authors declare that they have no competing interests.

![The three modules (module 1, module 2 and module 3) screened from the protein-protein interaction (PPI) network. The red circle nodes represent the upregulated genes, while the green circle nodes represent the downregulated genes.](IJMM-42-01-0021-g00){#f1-ijmm-42-01-0021}

![The TF-differentially expressed genes (DEG) regulatory network. The red nodes represent the upregulated genes, while the green nodes represent the downregulated genes. In addition, the triangle nodes stand for transcription factors, and circles nodes stand for their targeted genes.](IJMM-42-01-0021-g01){#f2-ijmm-42-01-0021}

![The DE-miRNA-DEG regulatory network. The red nodes represent the upregulated DEGs, while the green nodes represent the downregulated DEGs. In addition, the nodes in inverse triangle stand for miRNAs, and circles nodes stand for their targeted genes. DEGs: differentially expressed genes.](IJMM-42-01-0021-g02){#f3-ijmm-42-01-0021}

![The miRNA-function collaborative network of upregulated miRNAs. The pink circle nodes represent the biological process terms of Gene Ontology.](IJMM-42-01-0021-g03){#f4-ijmm-42-01-0021}

![The miRNA-function collaborative network of downregulated miRNAs. The pink circle nodes represent the biological process terms of Gene Ontology.](IJMM-42-01-0021-g04){#f5-ijmm-42-01-0021}

###### 

The DEGs associated with tumors.

  Category   Oncogene                                                                                                TSG                                                                                                                                                                                                                                                                                                                                                                                                                     TAG
  ---------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  UP         *CDC5L*, *FOSL1*, *HMMR*, *AURKA*, *MLF1*, *CDK4*, *MET*, *TRIO*, *NRAS*, *HOXA10*, *WHSC1*, *PIK3CA*   *S100A2*, *TUSC3*, *PAWR*, *LZTS1*, *YAP1*, *GADD45GIP1*, *PTPRG*, *RND3*, *DFNA5*, *HOXB13*, *BAI2*, *ZDHHC2*, *NF2*, *BCL10*, *FANCG*, *AMH*, *RCN2*, *HLTF*, *NME1*, *REV3L*, *DAPK3*, *FH*, *MEN1*, *HECA*, *TRIM3*, *SCRIB*, *BRMS1*, *EXTL3*, *SMARCB1*, *PCGF2*                                                                                                                                                  *TFAP2A*, *BUB1*, *NKX3-1*, *DNMT3B*, *PMS1*, *SHC1*, *YEATS4*, *FADD*, *C1QBP*
  DOWN       *FGF20*, *LYN*, *BCL6*, *TAL1*, *ESR1*, *WISP2*, *LMO2*, *LCN2*, *LYL1*                                 *HSD17B7*, *PRODH*, *MAL*, *DUSP22*, *TSC22D1*, *COL4A3*, *BAI3*, *BNIP3L*, *PER1*, *PAEP*, *RASSF4*, *FOXC1*, *EXTL1*, *ARHGAP20*, *CMTM5*, *NGFR*, *TXNIP*, *NOTCH1*, *MRVI1*, *MTSS1*, *MTUS1*, *PPAP2A*, *TCF4*, *ST5*, *PYHIN1*, *PRKCD*, *TGFBR3*, *CBFA2T3*, *MT1G*, *TSPAN32*, *RASSF2*, *CEBPA*, *LTF*, *RARRES1*, *MAP4K1*, *BTG2*, *PLA2G2A*, *ZBTB16*, *SYK*, *GPX3*, *PYCARD*, *H19*, *PTPN6*, *C2orf40*   *TAL2*, *WISP3*, *STAT3*, *CBLB*, *NR4A2*, *LYST*, *RGS2*, *FES*, *MGP*

TSG, tumor suppressor gene; TAG, tumor-associated gene.

###### 

The top 5 enriched GO functions in BP, CC and MF categories, as well as the top 10 enriched KEGG pathways separately for the upregulated and downregulated genes.

  Category     Term                                           Description                         Gene no.                            Gene symbol          p-value
  ------------ ---------------------------------------------- ----------------------------------- ----------------------------------- -------------------- ----------
  UP_BP        GO:0007049                                     Cell cycle                          133                                 *KPNA2*, *UBE2C*     0
  GO:0000278   Mitotic cell cycle                             90                                  *CDCA3*, *E2F7*                     2.22E-16             
  GO:0022402   Cell cycle process                             108                                 *FAM83D*, *SPC25*                   1.22E-15             
  GO:0051301   Cell division                                  62                                  *UBE2C*, *CDCA3*                    3.86E-14             
  GO:0048285   Organelle fission                              52                                  *FAM83D*, *SPC25*                   7.72E-14             
  UP_CC        GO:0005622                                     Intracellular                       611                                 *TFAP2A*, *CBS*      0
  GO:0031981   Nuclear lumen                                  161                                 *CBS*, *KPNA2*                      0                    
  GO:0043231   Intracellular membrane-bounded organelle       509                                 *KPNA2*, *JPH3*                     0                    
  GO:0044422   Organelle part                                 384                                 *SHROOM3*, *UBE2C*                  0                    
  GO:0044424   Intracellular part                             607                                 *FOXD1*, *UBE2C*                    0                    
  UP_MF        GO:0003824                                     Catalytic activity                  300                                 *PSAT1*, *UBE2C*     3.05E-10
  GO:0016740   Transferase activity                           123                                 *PSAT1*, *CCNB1*                    3.95E-09             
  GO:0005515   Protein binding                                382                                 *TFAP2A*, *CBS*                     1.13E-07             
  GO:0032549   Ribonucleoside binding                         115                                 *UBE2C*, *KIF2C*                    3.57E-06             
  GO:0035639   Purine ribonucleoside triphosphate binding     114                                 *SEPT3*, *PTK7*                     4.27E-06             
  DOWN_BP      GO:0001775                                     Cell activation                     104                                 *GRAP2*, *IL12RB1*   0
  GO:0001816   Cytokine production                            73                                  *STAT5B*, *LIPA*                    0                    
  GO:0002376   Immune system process                          252                                 *FGF20*, *FCGR3A*                   0                    
  GO:0002682   Regulation of immune system process            153                                 *BLK*, *CD200R1*                    0                    
  GO:0002684   Positive regulation of immune system process   99                                  *FCGR3A*, *GRAP2*                   0                    
  DOWN_CC      GO:0005576                                     Extracellular region                191                                 *FGF20*, *FCGR3A*    0
  GO:0005615   Extracellular space                            98                                  *CCL25*, *APOC2*                    0                    
  GO:0005886   Plasma membrane                                316                                 *IL12RB1*, *BLK*                    0                    
  GO:0044421   Extracellular region part                      120                                 *IL12RB1*, *BLK*                    0                    
  GO:0044459   Plasma membrane part                           174                                 *OPRD1*, *MAL*                      0                    
  DOWN_MF      GO:0097367                                     Carbohydrate derivative binding     29                                  *FGF7*, *TLR2*       1.55E-08
  GO:0005515   Protein binding                                417                                 *FGF20*, *HMGN3*                    3.54E-08             
  GO:0046983   Protein dimerization activity                  80                                  *ADD2*, *APOC2*                     5.30E-08             
  GO:0008307   Structural constituent of muscle               13                                  *DMD*, *MYL4*                       9.25E-08             
  GO:0042803   Protein homodimerization activity              55                                  *MZF1*, *ADD1*                      1.31E-07             
  UP_KEGG      01100                                          Metabolic pathways                  89                                  *CBS*, *PSAT1*       1.14E-06
  00100        Steroid biosynthesis                           7                                   *DHCR24*, *SQLE*                    2.02E-05             
  03040        Spliceosome                                    14                                  *CDC5L*, *SMNDC1*                   0.003765459          
  03008        Ribosome biogenesis in eukaryotes              10                                  *NXT2*, *NMD3*                      0.005664746          
  00270        Cysteine and methionine metabolism             6                                   *CBS*, *DNMT3B*                     0.007673661          
  00510        N-Glycan biosynthesis                          7                                   *TUSC3*, *ALG10B*                   0.009627025          
  00970        Aminoacyl-tRNA biosynthesis                    8                                   *MARS*, *YARS*                      0.011699718          
  00620        Pyruvate metabolism                            6                                   *ME1*, *ACAT2*                      0.012824724          
  00290        Valine, leucine and isoleucine biosynthesis    3                                   *BCAT1*, *VARS*, *LARS*             0.014647016          
  01040        Biosynthesis of unsaturated fatty acids        4                                   *PTPLA*, *ELOVL5*, *PTPLB*, *SCD*   0.017934809          
  DOWN_KEGG    05150                                          *Staphylococcus aureus* infection   21                                  *FCAR*, *C3AR1*      2.29E-12
  04640        Hematopoietic cell lineage                     21                                  *IL4R*, *CR1*                       4.15E-08             
  04145        Phagosome                                      27                                  *TLR2*, *NOX1*                      4.14E-07             
  05140        Leishmaniasis                                  17                                  *CR1*, *IFNGR1*                     9.79E-07             
  04060        Cytokine-cytokine receptor interaction         36                                  *CCL25*, *TNFSF8*                   3.76E-06             
  04380        Osteoclast differentiation                     22                                  *LILRA6*, *NOX1*                    7.87E-06             
  04650        Natural killer cell mediated cytotoxicity      22                                  *IFNGR1*, *NFATC3*                  2.14E-05             
  04514        Cell adhesion molecules (CAMs)                 21                                  *MAG*, *F11R*                       4.77E-05             
  05310        Asthma                                         9                                   *MS4A2*, *EPX*                      4.91E-05             
  05416        Viral myocarditis                              14                                  *DMD*, *SGCA*                       6.63E-05             

GO, Gene Ontology; BP, biological process; CC, cell components; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

The enriched KEGG pathways for the DEGs in module 1, module 2 and module 3 of the PPI network.

             Term                                           Description                   Gene no.                       Gene symbol        p-value
  ---------- ---------------------------------------------- ----------------------------- ------------------------------ ------------------ ----------
  Module 1   04114                                          Oocyte meiosis                7                              *AURKA, SGOL1*     2.04E-08
  04110      Cell cycle                                     7                             *PCNA, MCM2*                   4.16E-08           
  04914      Progesterone-mediated oocyte maturation        4                             *CCNB2, BUB1, MAD2L1, CCNB1*   0.000112373        
  04115      p53 signaling pathway                          3                             *CCNB2, CCNB1,GTSE1*           0.001071355        
  03430      Mismatch repair                                2                             *PCNA, EXO1*                   0.002163033        
  03030      DNA replication                                2                             *PCNA, MCM2*                   0.00526065         
  Module 2   04062                                          Chemokine signaling pathway   17                             *ADCY2, CX3CR1*    0
  04060      Cytokine-cytokine receptor interaction         15                            *CX3CR1, CXCR6*                9.77E-15           
  04080      Neuroactive ligand-receptor interaction        7                             *OPRD1, P2RY13*                9.93E-05           
  05150      Staphylococcus aureus infection                3                             *C3AR1, FPR1,C5AR1*            0.001547235        
  04916      Melanogenesis                                  3                             *ADCY2, POMC, GNAI1*           0.008639105        
  04620      Toll-like receptor signaling pathway           3                             *CCL3, CXCL9, CXCL10*          0.008876016        
  04672      Intestinal immune network for IgA production   2                             *CCL25, CCR9*                  0.017427247        
  04610      Complement and coagulation cascades            2                             *C3AR1, C5AR1*                 0.034329309        
  04971      Gastric acid secretion                         2                             *ADCY2, GNAI1*                 0.039017822        
  Module 3   03010                                          Ribosome                      8                              *RPL27A, RPL37A*   1.26E-12
  04141      Protein processing in endoplasmic reticulum    2                             *DDOST, SSR3*                  0.043084724        

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; PPI, protein-protein interaction.

###### 

The enriched GO functions for the upregulated and downregulated miRNAs involved in the DE-miRNA-DEG regulatory network.

  Category    Term                                                                        Description                                                       miRNA no.                            miRNA symbol          p-value
  ----------- --------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------ --------------------- -------------
  UP_BP       0048386                                                                     Positive regulation of retinoic acid Receptor signaling pathway   6                                    *miR-221, miR-18a*    0.000211583
  0060523     Prostate epithelial cord elongation                                         6                                                                 *miR-20b, miR-18a*                   0.001058491           
  0060745     Mammary gland branching involved in pregnancy                               6                                                                 *miR-221, miR-20b*                   0.001196154           
  0001766     Membrane raft polarization                                                  2                                                                 *miR-125a-5p, miR-128*               0.002429205           
  0030885     Regulation of myeloid dendritic cell activation                             2                                                                 *miR-125a-5p, miR-128*               0.002429205           
  0030887     Positive regulation of myeloid dendritic cell activation                    2                                                                 *miR-125a-5p, miR-128*               0.002429205           
  UP_MF       0031798                                                                     Type 1 metabotropic glutamate receptor binding                    6                                    *miR-221, miR-20b*    0.000150457
  0030235     Nitric-oxide synthase regulator activity                                    6                                                                 *miR-19b, miR-20b*                   0.000413057           
  0035256     G-protein coupled glutamate receptor binding                                6                                                                 *miR-19b, miR-18a*                   0.000413057           
  0030284     Estrogen receptor activity                                                  6                                                                 *miR-19a, miR-18a*                   0.002145221           
  0034056     Estrogen response element binding                                           6                                                                 *miR-19b, miR-19a*                   0.003216968           
  0031779     Melanocortin receptor binding                                               3                                                                 *miR-455-5p, miR-125a-5p, miR-484*   0.009585627           
  0031781     Type 3 melanocortin receptor binding                                        3                                                                 *miR-455-5p, miR-484, miR-125a-5p*   0.009585627           
  DOWN_BP     0014854                                                                     Response to inactivity                                            4                                    *miR-133b, miR-206*   0.001989302
  0014870     Response to muscle inactivity                                               4                                                                 *miR-1, miR-133b*                    0.001989302           
  0014877     Response to muscle inactivity involved in regulation of muscle adaptation   4                                                                 *miR-206, miR-1*                     0.001989302           
  0014894     Response to denervation involved in regulation of muscle adaptation         4                                                                 *miR-1, miR-133b*                    0.001989302           
  0002368     B cell cytokine production                                                  2                                                                 *miR-206, miR-1*                     0.002474699           
  0002424     T cell mediated immune response to tumor cell                               2                                                                 *miR-1, miR-206*                     0.002474699           
  DOWN\_ MF   0005008                                                                     Hepatocyte growth factor-activated receptor activity              4                                    *miR-133b, miR-206*   0.001415624
  0030955     Potassium ion binding                                                       4                                                                 *miR-206, miR-140-3p*                0.006643278           
  0031420     Alkali metal ion binding                                                    4                                                                 *miR-133b, miR-1*                    0.007459611           
  0003688     DNA replication origin binding                                              2                                                                 *miR-206, miR-1*                     0.014287542           
  0031078     Histone deacetylase activity (H3-K14 specific)                              4                                                                 *miR-206, miR-140-3p*                0.016613831           
  0032041     NAD-dependent histone deacetylase activity (H3-K14 specific)                4                                                                 *miR-1, miR-206*                     0.016613831           

DEG, differentially expressed gene; BP, biological process; MF, molecular function.

[^1]: Co-first authorship
